Treatment response and tolerability of frovatriptan in patients reporting short-or long-duration migraines at baseline

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2097-2104

  Kelman, Leslie ^a   Harper, Samira Q ^b   Hu, Xiaojun ^b   Campbell, John C ^b  

^a Headache Center of Atlanta   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Drug therapy; Frovatriptan; Migraine; Migraine duration; Postmarketing drug surveillance; Primary care; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ERGOTAMINE; FROVATRIPTAN; IBUPROFEN; METOCLOPRAMIDE; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ANALGESIA; ARTHRALGIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; GERMANY; HEADACHE; HEALTH CENTER; HEART PALPITATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE AURA; NAUSEA; PARESTHESIA; PHYSICIAN; POST HOC ANALYSIS; POSTMARKETING SURVEILLANCE; PRIMARY MEDICAL CARE; RECURRENT DISEASE; SCHOOL CHILD; SELF REPORT; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; TACHYCARDIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; ANALGESICS; CARBAZOLES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; SELF REPORT; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 77955629920     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.503488     Document Type: Article

References (30)

1. Kelman L. Pain characteristics of the acute migraine attack. Headache 2006;46:942-953
2. Adoukonou T, Houinato D, Kankouan J, et al. Migraine among university students in Cotonou (Benin). Headache 2009;49:887-893
3. Dahlof C, Linde M. One-year prevalence of migraine in Sweden: a populationbased study in adults. Cephalalgia 2001;21:664-671
4. Kallela M, Wessman M, Farkkila M, et al. Clinical characteristics of migraine in a population-based twin sample: similarities and differences between migraine with and without aura. Cephalalgia 1999;19:151-158
5. Wober-Bingol C, Wober C, Karwautz A, et al. Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia 2004;24:12-17
6. Silberstein S. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee for the American Academy of Neurology. Neurology 2000; 55:754-762
7. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. St. Paul, MN: US Headache Consortium (American Academy of Neurology, American Academy of Family Physicians, American Headache Society, American College of Emergency Physicians, American College of Physicians [American Society of Internal Medicine], American Osteopathic Association, National Headache Foundation); 2000
8. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006;13:560-572
9. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874-882 (Pubitemid 41045364)
10. Goldstein J, Tiseo PT, Albert KS, et al. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006; 46:1142-1150
11. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005;30:521-532 (Pubitemid 43960978)
12. Buchan P, Keywood C, Wade A, et al. Clinical pharmacokinetics of frovatriptan. Headache 2002;42:S54-62
13. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-388
14. Diener HC, Pfaffenrath V. Efficacy and tolerability of frovatriptan in practice-results of two postmarketing surveillance studies with 16,737 migraine patients. Nervenheilkunde 2007;26:180-185
15. Murtaza M, Kisat M, Daniel H, et al. Classification and clinical features of headache disorders in Pakistan: a retrospective review of clinical data. PLoS One 2009;4:e5827
16. Adeney KL, Flores JL, Perez JC, et al. Prevalence and correlates of migraine among women attending a prenatal care clinic in Lima, Peru. Cephalalgia 2006;26:1089-1096
17. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache 2002;42:185-193
18. Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000;20:701-707
19. Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-308
20. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707-716
21. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-353
22. Spierings EL, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med 2009;10: 633-638
23. Chia YC, Lim SH, Wang SJ, et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003;43:984-990
24. Diener HC, Gendolla A. Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany. Curr Med Res Opin 2005; 21:S18-24
25. Cady RK, Banks J, Jones BA, et al. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Curr Med Res Opin 2009;25:2711-2721
26. Wallasch TM. Frovatriptan in the practice of office-based neurologists/pain therapists: results of postmarketing surveillance study ALADIN. Adv Ther 2010;27:56-62; Epub Feb 6
27. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156-162
28. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-471
29. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513-520
30. Eich E, Reeves JL, Jaeger B, et al. Memory for pain: relation between past and present pain intensity. Pain 1985;23:375-380